The World Health Organization has designated AntiMicrobial Resistance (AMR) as one of the highest priority health and social challenges and one of the top 10 global public health threats facing humanity.

 More than 5,000,000 people die of drug-resistant infections every year, 10,000,000 by 2050

BIORIDIS responds to these important challenges and needs with its quick, reliable and easy to use QE-AMR assay. QE-AMR identifies antimicrobial resistant infections through detection of bacterial mRNA or small RNA. QE-AMR assay is based on our patented LIVELMIA technology and provided as a kit for quick and easy diagnosis. QE-AMR is a first in class technology.

The development was supported also by the EIT Health InnoStars Awards

#InnoStarsAwards2022, Final start-up https://lnkd.in/daSEyj_j, The Grand Final event: https://lnkd.in/dY_dBJpe

BIORIDIS, through its GEN-LIVELMIA software, can easily design and develop diagnostic kits specific for clinically relevant  bacteria

Bioridis developed a series of prototypes for the detection of genes responsible for AMR to test and validate its platform. 

*Priority developement for ESKAPE: 6 highly virulent and antibiotic resistant bacterial pathogens, 73% of deaths